MCID: NRN004
MIFTS: 56

Neuroendocrine Tumor

Categories: Cancer diseases, Endocrine diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Neuroendocrine Tumor

MalaCards integrated aliases for Neuroendocrine Tumor:

Name: Neuroendocrine Tumor 12 77 54 15
Neuroendocrine Neoplasm 12 54 30 6 17
Neuroendocrine Tumors 56 45 74
Carcinoma, Neuroendocrine 74
Neuroendocrine Neoplasia 54

Classifications:



External Ids:

Disease Ontology 12 DOID:169
ICD9CM 36 209 209-209.99
MeSH 45 D018358
NCIt 51 C3809
ICD10 34 D3A.8

Summaries for Neuroendocrine Tumor

NIH Rare Diseases : 54 A neuroendocrine tumor (NET) is a rare type of tumor that arises from specialized body cells called neuroendocrine cells. These cells have traits of both nerve cells and hormone-producing cells, and release hormones into the blood in response to signals from the nervous system. Because a neuroendocrine tumor arises from cells that produce hormones, the tumor can also produce hormones. Neuroendocrine tumors can develop anywhere in the body, but most occur in the digestive tract, pancreas, rectum, lungs, or appendix. They can be non-cancerous (benign) or cancerous (malignant). They usually grow slowly over many years, but there are fast-growing forms. There are many types of neuroendocrine tumors, but most are classified as one of two main types:Carcinoid tumors - NETs that most commonly arise in the digestive tract, lungs, appendix or thymus. They can also grow in the lymph nodes, brain, bone, gonads (ovaries and testes) or skin. Pancreatic neuroendocrine tumors (also called islet cell tumors) - NETs that typically arise in the pancreas, although they can occur outside the pancreas. A pheochromocytoma is another, rarer type of NET that usually develops in the adrenal gland, but can also arise in other parts of the body. Signs and symptoms depend on the tumor's type, size and location; whether it produces hormones; and whether it has spread to other parts of the body (metastasized). NETs are typically described as functional or nonfunctional. Functional NETs produce a specific set of symptoms due to the production of excess hormones, while non-functional NETs generally do not cause specific symptoms. In many cases, a person has no symptoms until the tumor spreads to the liver and/or impairs the function of an organ or system. This can make NETs very hard to diagnose. The majority of NETs are not inherited and occur sporadically in people with no family history of NETs. However, some NETs are associated with a hereditary cancer or tumor syndrome such as multiple endocrine neoplasia type 1 (most commonly), Von Hippel-Lindau disease, tuberous sclerosis, or neurofibromatosis type 1 (NF1). Inheritance of each of these is autosomal dominant. Treatment of NETs depends on many factors such as the tumor's type, location, aggressiveness, and hormone-producing capabilities; as well as whether it has metastasized. Management options may include surveillance, surgery to remove the tumor and/or surrounding tissue, and various non-surgical therapies to shrink the tumor, stop it from growing, or manage symptoms.

MalaCards based summary : Neuroendocrine Tumor, also known as neuroendocrine neoplasm, is related to gastrointestinal neuroendocrine tumor and esophageal neuroendocrine tumor. An important gene associated with Neuroendocrine Tumor is SST (Somatostatin), and among its related pathways/superpathways are Neuroscience and Neural Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Pancrelipase and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include lung, liver and brain, and related phenotypes are nervous system and no phenotypic analysis

Disease Ontology : 12 An endocrine gland cancer that has material basis in neuroendocrine cells.

Wikipedia : 77 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Related Diseases for Neuroendocrine Tumor

Diseases related to Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 425)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal neuroendocrine tumor 33.9 CHGA SST SYP
2 esophageal neuroendocrine tumor 33.4 CHGA NCAM1 SYP
3 gastric neuroendocrine neoplasm 33.0 CHGA GAST SST
4 insulinoma 32.7 CHGA INSM1 MEN1 SST
5 gastrinoma 32.4 CHGA GAST MEN1 SST
6 von hippel-lindau syndrome 32.3 CHGA CHGB MEN1
7 vipoma 32.2 CHGA GAST NTS SST
8 insulinomatosis and diabetes mellitus 32.1 CHGA GAST SST
9 gastric gastrinoma 32.1 ENO2 GAST
10 duodenal somatostatinoma 31.9 CALCA ENO2 SST
11 adrenal carcinoma 31.7 ENO2 MEN1 SYP
12 duodenal gastrinoma 31.5 CCK CHGA ENO2 GAST MEN1 SST
13 pancreatic cancer 31.2 CCK GAST MEN1 NTS SST SSTR2
14 multiple endocrine neoplasia 31.2 CALCA CHGA MEN1
15 multiple endocrine neoplasia, type i 30.7 CHGA GAST MEN1 SST SYP
16 acromegaly 30.5 MEN1 SST SSTR2
17 pernicious anemia 30.5 GAST SST
18 paraganglioma 30.4 CHGA ENO2 SST SYP
19 atrophic gastritis 30.3 CHGA GAST SST
20 growth hormone secreting pituitary adenoma 30.2 SST SSTR2
21 horseshoe kidney 30.2 CHGA ENO2 SYP
22 autoimmune atrophic gastritis 30.2 CHGA GAST
23 olfactory neuroblastoma 30.1 CHGA ENO2 SSTR2 SYP
24 goblet cell carcinoid 30.1 CHGA ENO2 GAST
25 glucagonoma 30.1 CHGA CHGB SST
26 pheochromocytoma 29.8 ASCL1 CALCA CHGA CHGB ENO2 MEN1
27 parathyroid adenoma 29.8 CALCA CHGA MEN1
28 ectopic cushing syndrome 29.8 MEN1 SST SYP
29 hemangioma 29.8 CHGA ENO2 SYP
30 pituitary carcinoma 29.8 CHGA SST
31 pulmonary large cell neuroendocrine carcinoma 29.8 CHGA ENO2 SYP
32 hyperparathyroidism 29.7 CALCA CHGA GAST MEN1
33 somatostatinoma 29.6 CALCA CHGA ENO2 SST
34 carcinoid syndrome 29.6 CALCA CHGA ENO2 MEN1 NTS SST
35 duodenal ulcer 29.6 CCK GAST SST
36 ependymoma 29.5 ENO2 MEN1 MKI67 SYP
37 diarrhea 29.5 CCK GAST SST
38 zollinger-ellison syndrome 29.4 CHGA GAST MEN1 NTS SST
39 gastrointestinal stromal tumor 29.3 CHGA ENO2 MEN1 MKI67 NCAM1 SYP
40 ganglioneuroma 29.2 CHGA ENO2 NCAM1 SYP
41 gallbladder small cell carcinoma 29.2 CHGA ENO2 NCAM1 SYP
42 large cell neuroendocrine carcinoma 29.0 ASCL1 CHGA ENO2 NCAM1 SYP
43 merkel cell carcinoma 28.9 CHGA ENO2 NCAM1 SST SYP
44 small cell carcinoma 28.8 CALCA CHGA ENO2 NCAM1 SYP
45 thyroid carcinoma, familial medullary 28.6 CALCA CCK CHGA CHGB ENO2 GAST
46 small cell cancer of the lung 27.8 ASCL1 CALCA CHGA ENO2 GAST INSM1
47 pancreatic neuroendocrine tumor 12.6
48 pulmonary neuroendocrine tumor 12.5
49 laryngeal neuroendocrine tumor 12.3
50 anal neuroendocrine tumor 12.3

Graphical network of the top 20 diseases related to Neuroendocrine Tumor:



Diseases related to Neuroendocrine Tumor

Symptoms & Phenotypes for Neuroendocrine Tumor

MGI Mouse Phenotypes related to Neuroendocrine Tumor:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.73 ASCL1 CCK CHGA CHGB ENO2 INSM1
2 no phenotypic analysis MP:0003012 9.23 ASCL1 CCK CHGA CHGB INSM1 MKI67

Drugs & Therapeutics for Neuroendocrine Tumor

Drugs for Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 732)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 53608-75-6
2
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 124-94-7 31307
3
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
4
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4342-03-4 5351166
5
Vindesine Approved, Investigational Phase 4 59917-39-4, 53643-48-4 40839
6
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 441203 84093 2767
7
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 108736-35-2
8
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 38916-34-6, 51110-01-1 53481605
9
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
10
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177 70789204
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 22916-47-8 4189
12
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 46835353 6436030 5284616
13
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 38904 10339178 498142
14
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
15
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 83150-76-9 6400441 383414
16
Sargramostim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
17
Pembrolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1374853-91-4
18
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
19
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 946414-94-4
20
Ipilimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 477202-00-9
21
Vemurafenib Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 918504-65-1 23252090 42611257
22
Palbociclib Approved, Investigational Phase 4,Phase 1,Phase 2 571190-30-2 11431660 5005498 5330286
23
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
24
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 85898-30-2, 110942-02-4
25
Etanercept Approved, Investigational Phase 4 185243-69-0
26
Doxazosin Approved Phase 4,Phase 3 74191-85-8 3157
27
Phenoxybenzamine Approved Phase 4,Phase 3 59-96-1 4768
28
Aminolevulinic acid Approved Phase 4 106-60-5 137
29
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 99011-02-6 57469
30
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
31
Dabrafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1195765-45-7 44462760 44516822
32
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
33
Gefitinib Approved, Investigational Phase 4,Phase 2,Not Applicable 184475-35-2 123631
34
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
35
Dasatinib Approved, Investigational Phase 4,Phase 1,Phase 2 302962-49-8 3062316
36
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
37
Ceritinib Approved Phase 4,Phase 2,Phase 1 1032900-25-6
38
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
39
Olaparib Approved Phase 4 763113-22-0 23725625
40
Lactitol Investigational Phase 4,Phase 1,Phase 2 585-86-4, 585-88-6 493591
41
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2,Early Phase 1 388082-78-8, 231277-92-2 208908 9941095
42 Fluorodeoxyglucose F18 Phase 4,Phase 2,Phase 1,Not Applicable
43 pancreatin Phase 4,Phase 1,Phase 2,Not Applicable
44 Anti-Bacterial Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
45 Gentamicins Phase 4,Not Applicable
46 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
47 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
48 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
49 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
50 Triamcinolone hexacetonide Phase 4,Phase 2,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 2697)
# Name Status NCT ID Phase Drugs
1 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Unknown status NCT02759718 Phase 4
2 Nonfunctional Pancreatic NET and PET Imaging Unknown status NCT02621541 Phase 4
3 Radiolabeled Molecules for Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
4 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Unknown status NCT02379754 Phase 4 Gentamicins
5 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
6 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4 Ranibizumab
7 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
8 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Completed NCT02075606 Phase 4 lanreotide acetate
9 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Completed NCT01525550 Phase 4 sunitinib
10 An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) Completed NCT01595009 Phase 4 Everolimus (RAD001)
11 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4 lanreotide (Autogel formulation)
12 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
13 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
14 Phenoxybenzamine Versus Doxazosin in PCC Patients Completed NCT01379898 Phase 4 Phenoxybenzamine;Doxazosin
15 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
16 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
17 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
18 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4 Imiquimod
19 Stereotactic Body Radiotherapy for Head and Neck Tumors Completed NCT01344356 Phase 4
20 A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide Recruiting NCT03289741 Phase 4 Octreotide;LAR Lanreotide
21 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4 everolimus
22 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Recruiting NCT03083210 Phase 4 Lanreotide
23 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Recruiting NCT01789281 Phase 4 Everolimus;Sandostatin LAR Depot
24 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
25 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
26 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
27 Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
28 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
29 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
30 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Active, not recruiting NCT02626065 Phase 4 Nivolumab
31 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4 Ipilimumab
32 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4 Zelboraf
33 Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies Not yet recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
34 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
35 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
36 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
37 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4 Pasireotide;Diazoxide
38 Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Unknown status NCT00171873 Phase 3 Octreotide LAR (Long-acting release);Placebo
39 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
40 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
41 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
42 Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
43 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
44 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
45 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3 DTIC (dacarbazine);paclitaxel + cisplatin;treosulfan + cytarabine
46 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
47 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
48 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
49 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3 histamine dihydrochloride
50 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3

Search NIH Clinical Center for Neuroendocrine Tumor

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: neuroendocrine tumors

Genetic Tests for Neuroendocrine Tumor

Genetic tests related to Neuroendocrine Tumor:

# Genetic test Affiliating Genes
1 Neuroendocrine Neoplasm 30

Anatomical Context for Neuroendocrine Tumor

MalaCards organs/tissues related to Neuroendocrine Tumor:

42
Lung, Liver, Brain, Thyroid, Skin, Lymph Node, Kidney

Publications for Neuroendocrine Tumor

Articles related to Neuroendocrine Tumor:

(show top 50) (show all 1336)
# Title Authors Year
1
Development of a Class Prediction Model to Discriminate Pancreatic Ductal Adenocarcinoma from Pancreatic Neuroendocrine Tumor by MALDI Mass Spectrometry Imaging. ( 30548962 )
2019
2
Analysis of pituitary adenoma expression patterns suggests a potential role for the NeuroD1 transcription factor in neuroendocrine tumor-targeting therapies. ( 30719226 )
2019
3
Gastric Neuroendocrine Tumor and Duodenal Gastrinoma With Chronic Autoimmune Atrophic Gastritis. ( 30531243 )
2019
4
Subacute Combined Degeneration, Pernicious Anemia and Gastric Neuroendocrine Tumor Occured Simultaneously Caused by Autoimmune Gastritis. ( 30740042 )
2019
5
Primary testicular neuroendocrine tumor with azoospermia: Extending indications for testicle-sparing surgery. ( 30705829 )
2019
6
Hepatocellular Carcinoma Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE PET/CT. ( 30688738 )
2019
7
Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor. ( 30877189 )
2019
8
Ectopic corticotropin-releasing hormone syndrome caused by pancreatic neuroendocrine tumor localized by 68Ga-DOTATATE PET/CT. ( 30519868 )
2019
9
The safety of lanreotide for neuroendocrine tumor. ( 30582380 )
2019
10
Diffuse Bone Metastases in Pancreatic Neuroendocrine Tumor Shown on Octreoscan. ( 30624276 )
2019
11
Rectal Submucosal Tumor Mimicking a Neuroendocrine Tumor. ( 30626842 )
2019
12
Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes. ( 30627774 )
2019
13
Primary Small Cell Neuroendocrine Tumor Within a Urethral Diverticulum. ( 30633138 )
2019
14
Necrobiotic Granuloma: A New Gastric Subepithelial Tumor Mimicking a Neuroendocrine Tumor. ( 30676367 )
2019
15
Utility of cytomorphology in distinguishing solid pseudopapillary neoplasm of pancreas from pancreatic neuroendocrine tumor with emphasis on nuclear folds and nuclear grooves. ( 30677247 )
2019
16
Risk of Infectious Complications After Simultaneous Gastrointestinal and Liver Resections for Neuroendocrine Tumor Metastases. ( 30691802 )
2019
17
Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor. ( 30702499 )
2019
18
Neuroendocrine Tumor of the Hilar Bile Duct. ( 30711974 )
2019
19
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. ( 30721156 )
2019
20
The Impact of Repeating Endosonography with Confocal Endomicroscopy for the Diagnosis of Cystic Neuroendocrine Tumor. ( 30755806 )
2019
21
Large Cell Neuroendocrine Tumor Size >3 cm Negatively Impacts Long-Term Outcomes After R0 Resection. ( 30783763 )
2019
22
C-reactive protein may be a prognostic factor for the whole gastroenteropancreatic neuroendocrine tumor group. ( 30788040 )
2019
23
Safety and Efficacy of Combined Peptide Receptor Radionuclide Therapy and Liver Selective Internal Radiation Therapy in a Patient With Metastatic Neuroendocrine Tumor. ( 30789395 )
2019
24
A Case of Streptozocin Monotherapy for Unresectable Duodenal Neuroendocrine Tumor G2. ( 30792640 )
2019
25
Combination of 5-Fluorouracil With Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression and Radioligand Binding in Neuroendocrine Tumor Cells in Vitro. ( 30796167 )
2019
26
Efficacy of Perioperative Endoscopic Naso-Pancreatic Drainage in Laparoscopic Enucleation of Pancreatic Nonfunctioning Neuroendocrine Tumor. ( 30819314 )
2019
27
Dual Imaging With 68Ga-DOTATOC and 18F-FDG PET for Planning and Follow-up of PRRT in Combination With Temozolomide Treatment in a Patient With a Metastatic Neuroendocrine Tumor. ( 30829861 )
2019
28
Abstracts of the 16th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease. ( 30844802 )
2019
29
Robotic Complete Mesocolic Excision for Right-Sided Neuroendocrine Tumor. ( 30844975 )
2019
30
Primary Renal Well-differentiated Neuroendocrine Tumor (Carcinoid): Next- Generation Sequencing Study of 11 Cases. ( 30851202 )
2019
31
Three trocars laparoscopic right ileocolectomy for advanced small bowel neuroendocrine tumor. ( 30851916 )
2019
32
Surgery for Pancreatic Neuroendocrine Tumor G3 and Carcinoma G3 Should be Considered Separately. ( 30863939 )
2019
33
The Search for an Alternative to [68Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of 18F-labeled Somatostatin Analog Development. ( 30867834 )
2019
34
A well-differentiated neuroendocrine tumor (Grade I) arising in a tailgut cyst. ( 30880789 )
2019
35
Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance. ( 30881119 )
2019
36
Clinicopathological features and prognosis factors for survival in elderly patients with pancreatic neuroendocrine tumor: A STROBE-compliant article. ( 30882623 )
2019
37
Preoperative diagnosis of well-differentiated neuroendocrine tumor in common hepatic duct by brush cytology: A case report. ( 30884200 )
2019
38
Neuroendocrine tumor of the appendix: Twelve years of results from a single institution. ( 30892667 )
2019
39
Correction to: Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. ( 30903344 )
2019
40
PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion. ( 30903445 )
2019
41
Paraneoplastic Syndrome Secondary to Treatment Emergent Neuroendocrine Tumor in Metastatic Castration-resistant Prostate Cancer: A Unique Case. ( 30279116 )
2019
42
Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). ( 30343949 )
2019
43
Brain Metastases of a Neuroendocrine Tumor Visualized by 68Ga-DOTATATE PET/CT. ( 30371585 )
2019
44
Evolution of a Schmorl's Node and a Degenerative Osteophyte on Sequential 68Ga-DOTATATE PET/CT Scans: Potential Pitfalls in Neuroendocrine Tumor Imaging. ( 30418207 )
2019
45
Demonstration of Treatment Response to Trans-arterial Radio-embolization (TARE) on 68Ga-DOTANOC PET/CT in a Patient With Metastatic Neuroendocrine Tumor. ( 29939955 )
2018
46
Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. ( 29503572 )
2018
47
Reply to: Genotype-Phenotype Pancreatic Neuroendocrine Tumor Relationship in Multiple Endocrine Neoplasia Type 1 Patients: A 23 Year Experience at a Single Institution. ( 29859614 )
2018
48
Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model. ( 29330294 )
2018
49
Hepatobiliary and Pancreatic: Malignant pancreatic perivascular epithelioid cell tumor mimicking pancreatic neuroendocrine tumor. ( 29888489 )
2018
50
Pancreatic neuroendocrine tumor: review of heterogeneous spectrum of CT appearance. ( 29594467 )
2018

Variations for Neuroendocrine Tumor

ClinVar genetic disease variations for Neuroendocrine Tumor:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CDKN1B NM_004064.4(CDKN1B): c.127delCinsTAA (p.Arg43Terfs) indel Likely pathogenic rs797044481 GRCh37 Chromosome 12, 12870900: 12870900
2 CDKN1B NM_004064.4(CDKN1B): c.127delCinsTAA (p.Arg43Terfs) indel Likely pathogenic rs797044481 GRCh38 Chromosome 12, 12717966: 12717966
3 CDKN1B NM_004064.4(CDKN1B): c.279_280insT (p.Pro94Serfs) insertion Likely pathogenic rs797044482 GRCh38 Chromosome 12, 12718118: 12718119
4 CDKN1B NM_004064.4(CDKN1B): c.279_280insT (p.Pro94Serfs) insertion Likely pathogenic rs797044482 GRCh37 Chromosome 12, 12871052: 12871053
5 CDKN1B NM_004064.4(CDKN1B): c.334delA (p.Ser112Alafs) deletion Likely pathogenic rs797044483 GRCh38 Chromosome 12, 12718173: 12718173
6 CDKN1B NM_004064.4(CDKN1B): c.334delA (p.Ser112Alafs) deletion Likely pathogenic rs797044483 GRCh37 Chromosome 12, 12871107: 12871107

Cosmic variations for Neuroendocrine Tumor:

9 (show top 50) (show all 62)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM17666 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.593T>C p.L198P 3:10149916-10149916 0
2 COSM14283 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.491A>G p.Q164R 3:10149814-10149814 0
3 COSM17662 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.492G>T p.Q164H 3:10149815-10149815 0
4 COSM17988 VHL adrenal gland,NS,pheochromocytoma,benign c.341-1G>T p.? 3:10146513-10146513 0
5 COSM18097 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.482G>A p.R161Q 3:10149805-10149805 0
6 COSM14311 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.499C>T p.R167W 3:10149822-10149822 0
7 COSM144972 VHL adrenal gland,NS,pheochromocytoma,benign c.245G>T p.R82L 3:10142092-10142092 0
8 COSM14321 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.227T>A p.F76Y 3:10142074-10142074 0
9 COSM5885100 VHL adrenal gland,adrenal gland,pheochromocytoma,malignant c.250G>A p.V84M 3:10142097-10142097 0
10 COSM6444479 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.260T>C p.V87A 3:10142107-10142107 0
11 COSM144971 VHL adrenal gland,NS,pheochromocytoma,benign c.244C>G p.R82G 3:10142091-10142091 0
12 COSM144975 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.475A>G p.K159E 3:10149798-10149798 0
13 COSM100047 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.389T>G p.V130G 3:10146562-10146562 0
14 COSM17982 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.496G>T p.V166F 3:10149819-10149819 0
15 COSM236660 VHL adrenal gland,adrenal gland,pheochromocytoma,benign c.250G>C p.V84L 3:10142097-10142097 0
16 COSM11071 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1009C>T p.R337C 17:7670700-7670700 0
17 COSM44175 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.644G>C p.S215T 17:7674887-7674887 0
18 COSM43931 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.523C>A p.R175S 17:7675089-7675089 0
19 COSM11286 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1015G>T p.E339* 17:7670694-7670694 0
20 COSM10801 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.404G>A p.C135Y 17:7675208-7675208 0
21 COSM10659 TP53 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.817C>T p.R273C 17:7673803-7673803 0
22 COSM966 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.1900T>C p.C634R 10:43114500-43114500 0
23 COSM965 RET adrenal gland,adrenal gland,pheochromocytoma,benign c.2753T>C p.M918T 10:43121968-43121968 0
24 COSM220089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1885G>A p.Q616fs*4 17:31225134-31225134 0
25 COSM329092 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1721+3A>T p.A548fs*13 17:31221932-31221932 0
26 COSM30670 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7646C>G p.S2549* 17:31356490-31356490 0
27 COSM329090 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.226G>T p.E76* 17:31159031-31159031 0
28 COSM5885098 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.5665G>T p.E1889* 17:31330351-31330351 0
29 COSM329093 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1722-1G>A p.? 17:31223443-31223443 0
30 COSM330587 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.205-1G>C p.R69Xfs*7 17:31159009-31159009 0
31 COSM327926 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.3158C>A p.S1053* 17:31230886-31230886 0
32 COSM327927 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7582C>T p.Q2528* 17:31352381-31352381 0
33 COSM33676 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.6855C>A p.Y2285* 17:31338739-31338739 0
34 COSM329087 NF1 adrenal gland,adrenal gland,pheochromocytoma,malignant c.4558C>T p.Q1520* 17:31260496-31260496 0
35 COSM3402726 NF1 adrenal gland,NS,pheochromocytoma,benign c.1307C>A p.S436* 17:31206286-31206286 0
36 COSM1710108 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.7300C>T p.Q2434* 17:31349230-31349230 0
37 COSM24441 NF1 adrenal gland,adrenal gland,pheochromocytoma,malignant c.3721C>T p.R1241* 17:31235623-31235623 0
38 COSM330588 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.2409+1G>A p.A776_Q803del 17:31227607-31227607 0
39 COSM329089 NF1 adrenal gland,adrenal gland,pheochromocytoma,benign c.1466A>G p.Y489C 17:31214524-31214524 0
40 COSM5946188 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.352A>T p.M118L 7:116699436-116699436 0
41 COSM707 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.3029C>T p.T1010I 7:116771936-116771936 0
42 COSM5967149 MET adrenal gland,adrenal gland,pheochromocytoma,benign c.607T>A p.S203T 7:116699691-116699691 0
43 COSM4445247 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.812G>C p.G271A 11:64807191-64807191 0
44 COSM4445249 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.808C>A p.L270M 11:64807195-64807195 0
45 COSM4445248 MEN1 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.1132G>T p.E378* 11:64805688-64805688 0
46 COSM4445246 MED12 adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning c.4857G>T p.K1619N 23:71134842-71134842 0
47 COSM496 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.181C>A p.Q61K 11:533875-533875 0
48 COSM499 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.182A>G p.Q61R 11:533874-533874 0
49 COSM486 HRAS adrenal gland,adrenal gland,pheochromocytoma,benign c.37G>C p.G13R 11:534286-534286 0
50 COSM1732355 H3F3A adrenal gland,adrenal gland,pheochromocytoma,benign c.103G>T p.G35W 1:226064454-226064454 0

Expression for Neuroendocrine Tumor

Search GEO for disease gene expression data for Neuroendocrine Tumor.

Pathways for Neuroendocrine Tumor

Pathways related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.56 CALCA ENO2 MKI67 NCAM1 SYP
2 11.23 ASCL1 NCAM1 SYP
3 9.8 CCK GAST

GO Terms for Neuroendocrine Tumor

Cellular components related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 CALCA CCK CHGA CHGB ENO2 GAST
2 secretory granule GO:0030141 9.5 CHGA CHGB SCG2
3 neuronal cell body GO:0043025 9.35 ASCL1 CALCA CCK ENO2 SST
4 terminal bouton GO:0043195 9.33 CALCA CCK SYP
5 extracellular region GO:0005576 9.28 CALCA CCK CHGA CHGB GAST NCAM1

Biological processes related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 9.88 CALCA CCK GAST NTS SST SSTR2
2 cellular protein metabolic process GO:0044267 9.56 CALCA CHGB MEN1 SCG2
3 positive regulation of neural precursor cell proliferation GO:2000179 9.43 ASCL1 INSM1
4 sympathetic ganglion development GO:0061549 9.37 ASCL1 INSM1
5 type B pancreatic cell differentiation GO:0003309 9.32 INSM1 MEN1
6 regulation of signaling receptor activity GO:0010469 9.17 CALCA CCK CHGB GAST NTS SCG2
7 noradrenergic neuron development GO:0003358 9.16 ASCL1 INSM1
8 adrenal chromaffin cell differentiation GO:0061104 8.96 ASCL1 INSM1

Molecular functions related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.02 CALCA CCK CHGB GAST SST

Sources for Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....